Search hospitals > Florida > Fort Lauderdale

Broward Health Medical Center

Claim this profile
Fort Lauderdale, Florida 33316
Global Leader in Breast Cancer
Global Leader in Cancer
Conducts research for Leukemia
Conducts research for Lymphoma
Conducts research for Acute Lymphoblastic Leukemia
244 reported clinical trials
8 medical researchers
Photo of Broward Health Medical Center in Fort LauderdalePhoto of Broward Health Medical Center in Fort Lauderdale

Summary

Broward Health Medical Center is a medical facility located in Fort Lauderdale, Florida. This center is recognized for care of Breast Cancer, Cancer, Leukemia, Lymphoma, Acute Lymphoblastic Leukemia and other specialties. Broward Health Medical Center is involved with conducting 244 clinical trials across 404 conditions. There are 8 research doctors associated with this hospital, such as Hector M. Rodriguez-Cortes, Brian Slomovitz, Shannon B. Keating, and Mehmet F. Hepgur.

Area of expertise

1Breast Cancer
Global Leader
Broward Health Medical Center has run 36 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
HER2 negative
ER positive
2Cancer
Global Leader
Broward Health Medical Center has run 31 trials for Cancer. Some of their research focus areas include:
Stage I
Stage IV
Stage II

Top PIs

Clinical Trials running at Broward Health Medical Center

Ovarian Cancer
Breast Cancer
Breast cancer
Cancer
Cervical Cancer
Lung Cancer
Uterine Cancer
Prostate Cancer
Testicular cancer
Wilms Tumor
Image of trial facility.

Mirvetuximab + Bevacizumab

for Ovarian Cancer

GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.
Recruiting2 awards Phase 3
Image of trial facility.

Trastuzumab Deruxtecan + Bevacizumab

for Ovarian Cancer

This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry \[IHC\] 3+/2+/1+) advanced high-grade epithelial ovarian cancer.
Recruiting2 awards Phase 35 criteria
Image of trial facility.

Olaparib +/- Bevacizumab

for Ovarian Cancer

This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving olaparib for one year with or without bevacizumab may be effective in treating patients with BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer, when compared to two years of olaparib.
Recruiting2 awards Phase 34 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Broward Health Medical Center?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security